Feb. 18, 2025 — The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study ...

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

As one of the leading causes of death worldwide, cancer and its many types have cut many lives short -- some of whom were ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Experimental autoimmune encephalomyelitis (EAE) is a model of the neuroimmune system responding to priming with central nervous system (CNS)-restricted antigens. It is an excellent model of post ...

After hours: February 20 at 6:18:57 PM EST Loading Chart for ACIU ...

After hours: February 21 at 4:05:02 PM EST ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.